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ABSTRACT
Allostery is the most direct, rapid and efficient way
of regulating protein function, ranging from the
control of metabolic mechanisms to signal-
transduction pathways. However, an enormous
amount of unsystematic allostery information has
deterred scientists who could benefit from this
field. Here, we present the AlloSteric Database
(ASD), the first online database that provides a
central resource for the display, search and
analysis of structure, function and related annota-
tion for allosteric molecules. Currently, ASD
contains 336 allosteric proteins from 101 species
and 8095 modulators in three categories (activators,
inhibitors and regulators). Proteins are annotated
with a detailed description of allostery, biological
process and related diseases, and modulators with
binding affinity, physicochemical properties and
therapeutic area. Integrating the information of allo-
steric proteins in ASD should allow for the identifi-
cation of specific allosteric sites of a given subtype
among proteins of the same family that can poten-
tially serve as ideal targets for experimental valid-
ation. In addition, modulators curated in ASD can be
used to investigate potent allosteric targets for the
query compound, and also help chemists to
implement structure modifications for novel allo-
steric drug design. Therefore, ASD could be a
platform and a starting point for biologists and me-
dicinal chemists for furthering allosteric research.
ASD is freely available at http://mdl.shsmu.edu.cn/
ASD/.
INTRODUCTION
Allostery, namely allosteric regulation, describes the regu-
lation of protein function, structure and/or ﬂexibility
induced by the binding of a ligand at a site topographic-
ally distinct from the orthosteric site (1). Such site is then
deﬁned as an allosteric site. With growing collection of
genome sequences and gene expression proﬁles, increasing
attention has been focused on protein function and regu-
lation in the post-genomic era (2). Allostery is the most
direct, rapid and efﬁcient way to regulate protein function,
ranging from the control of metabolic mechanisms to
signal-transduction pathways (3). Allosteric behaviors
are mostly found by the speciﬁc binding of metal ions or
molecules, which can alter cellular responses in order to
maintain homeostasis (1). Dysregulations of allosteric
systems are signiﬁcantly associated with human diseases,
such as Alzheimer’s disease, inﬂammation and diabetes
(4–6).
The ﬁrst cooperativity regulation was observed from the
sigmoidal-binding curve of hemoglobin to O2 in 1903 and
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aroused widespread concerns and led to the appearance of
the concept of ‘allosteric’ by Jacob and Monod (8,9).
Allosteric enzymes were ﬁrst summarized in the book of
Kurganov in 1978 (10), which collected a large amount of
experimental information and became a major allosteric
reference source. The allosteric family has now expanded
from multimeric proteins to monomeric proteins as well as
from native proteins to engineered proteins (11–13).
Intrinsically, the allosteric effect in a protein transmits
conformation change from the allosteric site to the
orthosteric site via atom ﬂuctuations, amino acid residue
networking or domain motion according to the distance
between the sites, eventually leading to the switch of func-
tions between two or more conformational states. A per-
sistent conformation ﬁxed by external factors is able to
function sustainably in the state (1).
A common factor for allosteric regulation derives from
the binding of metal ions and small molecules to the
allosteric sites as allosteric modulators, including activa-
tor/agonist, inhibitor/antagonist and other effector types
(see below) (1). Chemical allosteric modulators boasts
several advantages over orthosteric ligands as potential
therapeutic agents due to their quiescence in the absence
of endogenous-orthosteric activity, greater selectivity as a
result of higher sequence divergence in allosteric site and
limited positive or negative cooperation imposing a
‘ceiling’ on the magnitude of their allosteric effect (14).
In recent years, remarkable progress has been made in
the discovery, optimization and clinical development of
allosteric drugs of kinases, GPCRs and ion channels by
the pharmaceutical industry; for example, the develop-
ment of Gleevec (allosteric inhibitor of Abl) (15),
Cinacalcet (allosteric activator of calcium sensing
receptor) (14) and Maraviroc (allosteric inhibitor of
chemokine receptor 5) (14) promises exciting therapeutic
prospects with ﬁne regulation and fewer off target side
effects.
Despite its signiﬁcance and usefulness, an enormous
amount of unsystematic allostery information has
deterred scientists who could beneﬁt from this ﬁeld.
Specialized databases and analysis systems dedicated to
allostery are becoming crucial for capturing and
describing a rapidly increasing population of allosteric
molecules and for better understanding the mechanisms
of allosteric proteins and designing allosteric modulators
for drug discovery. In this work, we have developed the
AlloSteric Database (ASD), a comprehensive database of
allosteric proteins and their modulators. This is the ﬁrst
online database, to our knowledge, that focuses on ex-
haustive allostery information describing the speciﬁc
structure, function and mechanism of 336 allosteric
proteins and 8095 allosteric modulators, together with
their statistical evaluation, references to the scientiﬁc
literature and cross-links to other databases, such as
PubMed, UniProt (16), GenBank (17), Enzyme
Nomenclature (18), KEGG (19), PDB (20), SCOP (21)
and CATH (22). Furthermore, BLAST search engine for
proteins and chemical structure search engine for small
modulators are available as web-based tool for allosteric
recognition. Taken together, ASD is an integrated
resource that could provide useful information and tool
for the investigation of allosteric mechanism as well as
novel drug design and protein engineering.
MATERIALS AND METHODS
Information on allostery was collected from scientiﬁc
literature and various web resources: e.g. IUPARM (23),
Drugbank (24) and PDB (20). Some information was
gathered from United States Patent and European
Patent ﬁles. First, 16425 abstracts of PubMed were auto-
matically ﬁltered for relevant articles using ‘alloster*’ as
keyword. The names of allosteric proteins were then
extracted from the abstracts to clusters by a protein
name dictionary constructed from UniProt (16), retrieving
500 distinct biological proteins. A team of scientists
manually processed the papers with respect to the clus-
tered names. With at least three cases of experimental
evidence in crystal structure complex or biochemistry
(inactive mutation of allosteric residue, cooperativity of
kinetic effect from two ligands and uncompetitive-binding
assay with chromatography, etc.), 336 proteins supporting
their functional change elicited by modulator binding at a
site that was topographically distinct from the orthosteric
functional site, were veriﬁed as allosteric proteins for de-
position into the ASD. All proteins in the ASD were
annotated with gene information, biological function,
natural mutations and related diseases extracted from
GenBank (17), Uniprot (16), Enzyme Nomenclature (18)
and original literature. An up-to-date synchronization on
available structures of allosteric proteins from PDB is
present and their structural classiﬁcation SCOP (21) and
CATH (22) based on the PDB ID are also labeled.
Large-scale allosteric conformational changes, such as
open–close and twist, inferred from multiple conform-
ational structures of allosteric proteins, were manually
annotated to the allosteric mode ﬁeld. Theoretical
models of allosteric proteins without structures were
generated with I-TASSER (25) or built manually using
Modeller (26) when C-score of the best I-TASSER
model is below 1.5 or high-homologous oligomeric tem-
plates are available in PDB. All structures are download-
able as PDB ﬁles. Notably, extensive descriptions of
allosteric sites were summarized from literature and the
sites were always highlighted in the diagram of protein
topologies (27,28) if they have been explicitly validated
by biochemistry or structure biology.
Second, after all allosteric proteins with relevant anno-
tation information were collected, we further searched for
allosteric modulators for the 336 allosteric proteins. All
the abstracts from PubMed, United States Patent and
European Patent ﬁles containing ‘allosteric modulator/
effector/activator/inhibitor/agonist/antagonist’ in combin-
ation with the name of the collected allosteric proteins
were curated and then manually identiﬁed as the ﬁnal
set, resulting in the collection of 8095 chemical allosteric
modulators with respective references. Meanwhile,
publicly available binding afﬁnities of the allosteric modu-
lators to their allosteric sites in the proteins were also
obtained from the references. Among the allosteric
D664 Nucleic AcidsResearch, 2011, Vol.39, Database issuemodulators in the ASD, those that increase a particular
protein function, for example, orthosteric ligand afﬁnity
or catalytic rate, are classiﬁed as ‘allosteric activator’ or
‘A’. Those that decrease a particular protein function are
classiﬁed as ‘allosteric inhibitor’ or ‘I’. The remaining
modulators, which control cooperativity of multimeric
proteins, regulate the enzyme indirectly under allosteric
control via the bound protein with an allosteric site,
induce a new binding site to a protein, etc., are classiﬁed
to the ‘allosteric regulator’ or ‘R’ category. Since allosteric
modulators were initially identiﬁed from endogenous
ligands and then widely accepted for the development of
novel types of drugs, the tags ‘Endogenous’ and
‘Druggable’ in the ASD differentiate allosteric modulators
produced in vivo and designed for drug use, respectively.
In addition, important physicochemical properties used in
drug discovery, such as logP, PSA, the number of rotat-
able bonds, etc., were calculated on the allosteric modula-
tors by Filter Program from Openeye (http://www
.eyesopen.com). Each modulator in the ASD is download-
able as 2D mol and 3D mol2 ﬁles.
ASD is designed as a relational database on a MySQL
server (Figure 1). For visual inspection of 2D chemical
structures, MarvinView (http://www.chemaxon.com) is in-
stalled. For displaying 3D structures, Jmol (http://www
.jmol.org/)—an open source Java viewer for proteins
and chemical structures in 3D—is used. MarvinSketch is
applied as a built-in molecule editor, which allows users to
query the database using self-edited molecules. The web
site is built with Ajax framework ExtJS with EJB3, Web
access is enabled via JBOSS Webserver. Internet Explorer
version 7 or above, Mozilla Firefox version 3.6 or above,
Apple Safari and Google Chrome were thoroughly tested
and thus recommended for ASD.
RESULT
The ASD database
ASD is a comprehensive database on allosteric informa-
tion. It contains two types of data: (i) allosteric proteins;
(ii) small allosteric modulators identiﬁed from in vitro
binding to the allosteric proteins at the allosteric site. In
total, 336 allosteric proteins and 8095 chemical allosteric
modulators are curated and fully annotated by the
database developers and experts in the ﬁeld.
Allosteric proteins in ASD cover 101 different species,
of which 34% of the allosteric proteins are from human
and 25% from bacteria (Figure 2B). Crystal structures of
3580 redundant proteins are provided from PDB and 156
of them explicitly show allosteric sites. Based on the
known structures, theoretical 3D models of the remaining
220 missing allosteric structures from 50 species are
constructed and downloadable from ASD. We have
analyzed the occurrence of allosteric proteins in the struc-
tural hierarchies represented in SCOP and CATH. Class
with mainly ‘alpha/beta’ in SCOP and ‘mixed’ in CATH
Figure 1. The basic framework of ASD. All results generated by ASD are deposited in MySQL and displayed in the visual browser and web pages.
The web-interface programs and browser can be accessed by a wide range of research biologists and chemists to analyze and visualize data over the
internet.
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which indicates that secondary structures of a certain
scale are important in allostery. More and more allosteric
proteins have been revealed to be disease causing when
abnormal and some of them used as drug targets.
Therefore, 248 diseases from irregular allostery are also
included in ASD.
Currently, ASD contains 8095 allosteric modulators. Of
them, 4784 activators, 3035 inhibitors and 386 regulators
were veriﬁed in literature to be associated with corres-
ponding allosteric proteins, and only 101 modulators
(1.2%) play multiple roles in different allosteric systems
as shown in Figure 2C. Thus, 8680 allosteric interactions
between proteins and modulators are deposited into ASD.
An overwhelming portion of the modulators is organic
small molecules (8062, 99.6%), followed by ions (27,
0.33%) and peptides (6, 0.07%). Since almost all allosteric
hits/leads/drugs were initially derived from endogenous
molecules and then screened and modiﬁed in drug
discovery, ASD now holds 244 endogenous allosteric
seeds and 7481 compounds in the pipeline of drug
discovery.
Web interface
ASD provides a variety of interfaces and graphical visu-
alizations to facilitate viewing and analysis of the allosteric
molecules (proteins and modulators) from structures,
functions and related properties. As shown in
Supplementary Figure S1 in the supporting information,
ASD presents the three starting points of browsing ASD
and three search options. To visually understand the data
in ASD, browsing and searching tools are fully
crosslinked. One can quickly jump from search results to
their full pages of browsing so that the users can analyze
data more efﬁciently. For example, users can start by
searching the name of an allosteric molecule and visualize
a complete description in the browsing page and then
download the speciﬁc molecule for further review.
Figure 2. Statistics on the allosteric proteins and modulators. (A) Class distribution of allosteric proteins. (B) Species distribution of allosteric
proteins. (C) Category distribution of allosteric modulators. (D) A history of the discovery of allosteric modulators.
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ecules and related structural and function annotation by
providing three ‘Search’ tools—‘Blast search’, ‘Modulator
search’ and ‘Text search’. ‘Blast search’ is powered by
PSIBLAST (29) and is particularly useful as it allows
users to quickly identify allostery by comparing the
query proteins to known allosteric proteins in ASD. The
search is triggered by pasting a FASTA format sequence
and pressing the ‘search’ button, resulting in a list of
similar allosteric proteins reported in terms of E-values.
A signiﬁcant hit reveals the possibility that the query
protein may act with allostery in a way similar to the
allosteric template. In addition, the speciﬁc allosteric site
in the concerned allosteric protein could be validated by
alignment to other family proteins. ‘Modulator search’
can be used to design novel allosteric compounds of
known allosteric proteins in ASD. User may sketch
(through Marvin’s freely available chemical sketching
applet) or paste a SMILES string (30) of a possible allo-
steric compound into the Modulator search window.
Submitting the query launches a structure similarity
search tool that looks for common features from the
query compound that match known allosteric modulators
in ASD. High-score hits are ranked in a tabular format
with hyperlinks to the corresponding full description and
in turn to links to the allosteric protein target. The
‘Modulator search’ tool allows users to quickly determine
whether their compound of interest acts on the desired
allosteric protein target and reveal whether the
compound of interest may unexpectedly interact with un-
intended allosteric protein targets. In addition to these
structure similarity searches, the Modulator search
utility also supports compound searches on the basis of
physicochemical properties and chemical formulas. ‘Text
search’ provides users a global tool to search throughout
ASD by typing a single term, such as a name, a PDB
identiﬁer or a species that is related to an allosteric
molecule of interest and the server will return a list of
links to relevant entries. Each entry contains a brief intro-
duction of the allosteric molecule with a hyperlink to its
full page.
The ‘Browse’ tools in the database facilitate easy re-
trieval of information from ASD through three categories:
‘Modulator browse’, ‘Target browse’ and ‘Index browse’.
‘Modulator browse’ is used to visualize all allosteric
modulators with 2D structures and synoptic description
in the tab of ‘All’ or three respective categories
(‘Activator’, ‘Inhibitor’ and ‘Regulator’) at the ﬁrst level,
in which each entry links to its second level for exhaustive
description of interest. The detailed annotation contains
name of the molecule, molecular weight, interactive
applets for viewing 2D and 3D molecular structures,
>30 drug-like physicochemical properties and experimen-
tally validated allosteric targets with hyperlinks to refer-
ences. This is designed for pharmacists and medicinal
chemists who work closely with the quantitative struc-
ture–property relationship of allosteric modulator.
‘Target browse’ allows user to preview the list of names
of allosteric proteins under class tabs of ‘Kinase’, ‘GPCR’,
‘Channel’, ‘E-protein’ and ‘Other’ at the ﬁrst level
(Figure 2A) and a quick navigation of allosteric protein
of interest in all validated species integrated at a panel of
the second level is shown by clicking on the link from the
ﬁrst level. Next, checking on the selected species in the
panel will open a new browser window with a detailed
view of the corresponding allosteric protein being dis-
played, including sequence, structure, native mutation,
protein modiﬁcation and allosteric description. As with
most biological databases, all of the proteins illustrated
in ASD are hyperlinked to other online databases or
tables like UniProt, GenBank, Enzyme Nomenclature,
KEGG or PDB. By hyperlinking to these particular data-
bases, ASD is able to provide considerably more informa-
tion about allosteric proteins. ‘Index browse’ allows the
browsing of any allosteric molecules by their names, which
are arranged in alphabetical sequence within each initial
letter tab.
In addition to the ‘Browse’ and ‘Search’ options, ASD
also offers background glossary and diagram under its
‘Allosteric Wiki’ menu; allosteric news, meeting, refer-
ences and signiﬁcant ﬁnding under its ‘Hot Topics’
menu; release note, statistical information, ‘Expert’
platform for communication of allosteric information to
external experts and data download under its ‘About’
menu; and miscellaneous links to other databases under
its ‘Links’ menu.
DISCUSSION AND CONCLUSIONS
ASD is a manually curated database dedicated to
allosteries involving receptors and ligands. It is the ﬁrst
online resource of this kind and the data in ASD are freely
available to all potential users. We harvested experimen-
tally veriﬁed allosteric proteins and modulators from sci-
entiﬁc articles. Of 336 allosteric proteins in ASD, 205
(66.96%) proteins catalyze diverse biological reaction as
enzyme included by Enzyme Nomenclature (18) and 283
(84.23%) proteins are contained in KEGG (19). Contrary
to the proteins, >95% allosteric modulators are not
covered by two important bio-active small molecule data-
bases viz, Drugbank (4.49%) (24) and ChEMBL (0.2%)
(31). These allosteric data are accompanied by additional
information about their structures, functions, related
diseases, external links and associated tools, which may
provide a valuable resource for research on the allosteric
ﬁeld.
Our initial collection mainly focused on allosteric
proteins and their modulators, which have been extensive-
ly studied for >50 years. More than 300 proteins were
found as allostery and thus allosteric protein is inter-
changeable with the term allosteric macromolecules.
However, the other type of macromolecules, namely the
nucleic acids (DNA and RNA), was recently found to
match the rule of allostery in several cases (32–34).
Considering the fact that these allosteries are not widely
conﬁrmed, nucleic acids are not included in the current
version but will be added into ASD in the next version.
ASD provides users with both chemical and biological
tools for information mining on allosteric molecules.
Chemical searches can suggest similar structures of
molecules/scaffolds from known allosteric modulators.
Nucleic Acids Research, 2011,Vol.39, Database issue D667Such parallel molecules with known targets in ASD can
assist in the recognition of potent allosteric targets for
query compound, and such comparable scaffolds can
facilitate the structural modiﬁcations necessary for novel
allosteric drug design. On the biological side, there is a
tool that supports search based on sequence similarities
of proteins. Combining the information in ASD with
sequence alignment should allow for the prediction of
allostery for proteins with unknown properties. In
addition, high homology between the subtypes of family
proteins to some extent hampered the progress of func-
tional identiﬁcation in the ﬁeld of both chemical biology
and drug discovery. The allosteric site of one subtype
aligned to other members of a protein family could
provide clues to its potential speciﬁc features and eventu-
ally make it ideal target for experimental validation.
FUTURE DIRECTIONS
As a resource to study the allosteric world, we will
continue updating the database with allosteric proteins
and their modulators every 6 months and respond to
‘Expert’ request within 1 week. We have also extended
allosteric collection and analysis to another type of macro-
molecule, the nucleic acids including DNA and RNA. On
the other hand, in order to clarify the biological behavior
of allosteric modulators identiﬁed in screenings, a novel
algorithm for recognition of allosteric sites is currently
being developed. We believe such integrative allosteric
data and tools will give users the expanded knowledge
needed for the biological and chemical interpretation of
each allosteric event.
AVAILABILITY AND REQUIREMENTS
ASD is freely available at http://mdl.shsmu.edu.cn/ASD/.
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Supplementary Data are available at NAR Online.
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